A Phase 4 interventional study of Ropivacaine 0.2% Injectable Solution and Ropivacaine 0.2% Injectable Solution in Knee Arthritis, Knee Arthropathy and Knee Osteoarthritis, sponsored by Poznan University of Medical Sciences. Completed at 1 site in Poland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Poznan University of Medical Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing ropivacaine in Osteoarthritis, Knee — 1 open to participants now, 2 under way, none of them phase 3. Ropivacaine · Osteoarthritis, Knee.
Among the 18 studies testing ropivacaine in Osteoarthritis, Knee, this one is the 11th largest by enrollment, is one of 4 that started in 2024, is one of 15 in phase 4, and was the 16th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →1 of the 18 studies testing ropivacaine in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:
Poznan University of Medical Sciences · Sites in Poland
Ages 65–100
By country, each count listing its studies:
Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 64 across the 18 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Poznan University of Medical Sciences is the lead sponsor of 152 studies on the registry; 42 are open to participants now.
13 studies in Osteoarthritis, Knee by Poznan University of Medical Sciences: 2 open now, 3 under way, none of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 13 studies in Osteoarthritis, Knee by Poznan University of Medical Sciences, this one is the 9th largest by enrollment, is one of 6 that started in 2024, is one of 9 in phase 4, and was the 5th registered.
Poznan University of Medical Sciences’s Osteoarthritis, Knee studies by the year they started, since 2020.
1 of the studies testing ropivacaine in Osteoarthritis, Knee that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07449442Poznan University of Medical SciencesSII Levels Following iPACK Block With Adductor Canal Block in Knee Arthroplasty | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing ropivacaine in Osteoarthritis, Knee, from their registry updates:
Among Poznan University of Medical Sciences’s 13 in Osteoarthritis, Knee:
This tab as a report to print or save as PDF → With an account.
Effect of iPACK block with Adductor Canal Block and ESPB on pain management, and NLR and PLR following knee arthroplasty
Knee arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. Patients may complain of severe pain due to surgical trauma and prostheses. Regional anaesthesia methods may be performed to reduce the surgery's induced stress response, opioid consumption, and opioid-related side effects.
In recent years, the influence of regional anesthesiology on reducing the inflammatory response after surgical procedures has been emphasised. However, very few studies have evaluated the effect of various methods of anaesthesia on the NLR and PLR.
This is the first study to investigate the effect of regional anaesthesia on the pain managementonse expres and stress respsed by the NLR and PLR in patients undergoing knee replacement surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
spinal anesthesia \+ ultrasound guided iPACK (20ml 0,2% ropivacaine) with ACB (10ml 0.5% ropivacaine)
Drug: Ropivacaine 0.2% Injectable Solution
spinal anesthesia \+ ultrasound guided ESPBk - 20ml 0,2% ropivacaine
Drug: Ropivacaine 0.2% Injectable Solution
Only spinal anesthesia - No peripheral nerve block
Drug: control group
iPACK block + Adductor Canal Block
Also known as: iPACK + ACB
Erector Spinae Plane Block
Also known as: ESPB
only spinal anesthesia
Also known as: only spinal anesthesia
Opioid consumption
Total opiate consumption after surgery
Time frame: 48 hours after surgery
Time to first rescue opiate analgesia
Time after surgery when the patient needs opiate for the first time
Time frame: 48 hours after procedure
Numerical Rating Scale [range 0:10]
Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)
Time frame: Time Frame: 4 hours after surgery
Numerical Rating Scale [range 0:10]
Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)
Time frame: Time Frame: 8 hours after surgery
Numerical Rating Scale [range 0:10]
Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)
Time frame: Time Frame: 12 hours after surgery
Numerical Rating Scale [range 0:10]
Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)
Time frame: Time Frame: 16 hours after surgery
Numerical Rating Scale [range 0:10]
Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)
Time frame: Time Frame: 20 hours after surgery
Numerical Rating Scale [range 0:10]
Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)
Time frame: Time Frame: 24 hours after surgery
Numerical Rating Scale [range 0:10]
Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)
Time frame: Time Frame: 36 hours after surgery
Numerical Rating Scale [range 0:10]
Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)
Time frame: Time Frame: 48 hours after surgery
Neutrophil-to-lymphocyte ratio
Neutrophil-to-lymphocyte ratio
Time frame: 24 hours after surgery
Neutrophil-to-lymphocyte ratio
Neutrophil-to-lymphocyte ratio
Time frame: 48 hours after surgery
Platelet-to-lymphocyte ratio
Platelet-to-lymphocyte ratio
Time frame: 24 hours after surgery
Platelet-to-lymphocyte ratio
Platelet-to-lymphocyte ratio
Time frame: 48 hours after surgery
Quadriceps muscle strength assessed using medical research council scale [range 0:5]
Quadriceps muscle strength (knee extension and hip adduction) will be evaluated according to the medical research council muscle strength rating
Time frame: Postoperative 24 hours period
Plan to share: Yes — Please provide the plan description
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: 6 month after study completion
Access criteria: from the corresponding author on the resonable request
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Aug 2024, 5 months.
Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's 5 months is below that.
Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Apr 2024 → Mar 2024, primary completion Sep 2024 → Aug 2024 and completion Oct 2025 → Sep 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
Poznan University of Medical Sciences →